Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Opus GeneticsIRD | Open-market sale | 05/18 | 05/20 | 1,700,000 sh | $4.35 | $7,395,000 | −31.0% | |
Benjamin R. YerxaPresident | Opus GeneticsIRD | Open-market sale | 04/23 | 04/27 | 7,470 sh | $5.24 | $39,142.8 | −1.0% |
Opus GeneticsIRD | Open-market sale | 04/23 | 04/27 | 4,697 sh | $5.22 | $24,518.34 | −1.6% | |
Opus GeneticsIRD | Open-market sale | 04/23 | 04/27 | 7,842 sh | $5.18 | $40,621.56 | −1.3% | |
Rabourn Amy ZarembaHead of Fin. Quality Assurance | Opus GeneticsIRD | Open-market sale | 04/23 | 04/27 | 1,641 sh | $5.20 | $8,533.2 | −0.9% |
Opus GeneticsIRD | Open-market sale | 04/23 | 04/27 | 9,511 sh | $5.22 | $49,647.42 | −0.5% | |
Ashwath JayagopalChief Scientific & Dev. Ofc | Opus GeneticsIRD | Open-market sale | 04/23 | 04/27 | 7,542 sh | $5.19 | $39,142.98 | −1.5% |
Opus GeneticsIRD | Open-market sale | 03/16 | 03/18 | 3,719 sh | $5.25 | $19,524.75 | −1.2% | |
Rabourn Amy ZarembaHead of Fin. Quality Assurance | Opus GeneticsIRD | Open-market sale | 03/16 | 03/18 | 2,816 sh | $5.25 | $14,784 | −1.5% |
Opus GeneticsIRD | Open-market sale | 03/16 | 03/18 | 24,438 sh | $5.21 | $127,321.98 | −1.4% | |
Ashwath JayagopalChief Scientific & Dev. Ofc | Opus GeneticsIRD | Open-market sale | 03/16 | 03/18 | 3,719 sh | $5.12 | $19,041.28 | −0.7% |
Opus GeneticsIRD | Open-market buy | 25/12/29 | 25/12/31 | 164,000 sh2 trades | $1.97avg. | $323,890 | No record | |
Opus GeneticsIRD | Open-market sale | 25/12/09 | 25/12/11 | 4,000,000 sh | $2.15 | $8,600,000 | −42.1% | |
Opus GeneticsIRD | Open-market buy | 24/12/26 | 24/12/30 | 100,000 sh | $0.98 | $98,000 | +20.0% | |
Benjamin R. YerxaPresident | Opus GeneticsIRD | Open-market buy | 24/11/21 | 24/11/25 | 10,000 sh | $0.98 | $9,800 | +3.0% |
Opus GeneticsIRD | Open-market buy | 24/11/15–24/11/18 | 24/11/19 | 100,000 sh2 trades | $1.01avg. | $101,097.06 | +25.4% |